EQT Leads, Batch 12026-08-03

Velora Health

Profitable Stockholm AI-healthtech growing revenue 4.3x year-over-year in public filings, with zero funding press. Chaired by the founder of Proxify (493 MSEK revenue).
Preemptive Series A ← All leads
Founded
2023Stockholm (559455-0724)
Revenue FY2025
18.4 MSEK+325% YoY, profitable
Employees
123 → 5 → 12 across filings
Disclosed funding
Noneno rounds announced
Status
Quietno press, hiring hard
Why this fits the sweetspotTraction has demonstrably hit, revenue 1.4 → 4.3 → 18.4 MSEK across three filed periods, profitable, headcount 4x, and there is no announced round, no press, and no banked process anywhere in the public record. If the growth is venture-shaped (see caveats), this is a Series A conversation nobody else is having yet.
01

What the company does

Velora Health describes itself as "a rapidly growing AI HealthTech startup on a mission to address the leading causes of preventable death" (its own hiring copy). Its registered purpose is healthcare technology, services and systems. The engineering job ads show an active consumer-grade product build (React Native mobile app, TypeScript backend). The company runs quiet: no marketing site was found on common domains, while active recruiting for a Head of Growth reporting to the CEO and full-stack engineers is live.

02

Founders & leadership

Vidar Laestadius: CEO and founder (b. 1989); named CEO in the corporate registry and bylined "CEO and Founder of Velora Health" on the company's own hiring posts. Michael Berg: Chairman (b. 1964); chairman of Proxify AB, the Stockholm developer-talent company with 493 MSEK revenue in its latest filed accounts, giving Velora scaled-operator governance from day one.

03

Traction, from the filings, not the press

Filed annual accounts show: 1.43 MSEK (period to Jun 2024) → 4.32 MSEK (FY to Dec 2024) → 18.38 MSEK (FY to Dec 2025), with a positive net result (+0.93 MSEK) and average headcount rising 3 → 5 → 12. Profitable at this growth rate implies real willingness-to-pay rather than subsidized growth.

04

Market context, the preventive-health repricing

Swedish preventive health is the Nordics' hottest consumer-health category: Neko Health (Daniel Ek's body-scanning company, Stockholm) raised €60M from Lakestar and Atomico on the thesis that consumers will pay out of pocket for early detection. Velora's own positioning language ("address the leading causes of preventable death") places it in the same wave, but profitable and self-funded rather than capital-heavy. If its model is a software/coaching layer rather than clinics, the margin profile beats the category leader's.

05

Round status, the preemptive window

No funding round, investor, or raise intention appears anywhere in the public record (checked 2026-08-03 across press, funding databases and the company's own surfaces). The company appears bootstrapped or quietly angel-funded. That cuts both ways: the window is genuinely open, and the founders may not currently be seeking capital, a relationship-first approach fits.

06

What the public record does not disclose

The product's exact form and customer mix (B2C app vs B2B contracts) is not publicly stated; the revenue could include services. Cap table and any unannounced angel capital are unknown. The growth curve is registry-verified; its venture-scalability is not. First diligence question: what exactly generated the 18.4 MSEK.